#ACTRIMS26：赛诺菲公布托莱布替尼治疗原发性进展型多发性硬化症三期试验失败数据

Thermo FisherTMO Thermo Fisher Scientific Inc falls 2.95 percent post Q4 2025 earnings despite narrow EPS beat and 3.9 percent year-over-year revenue growth. - Investment Community Signals - UBND thành phố Hải Phòng

FierceBiotech礼来公司放弃与瑞格生物剩余协议，RIPK1抑制剂再遭打击。

Thermo FisherThermo Fisher (TMO) Q4 2024 Earnings Transcript - AOL.com

WatersWAT (Waters Corporation) rises 1.06 percent after Q4 2025 results, as 7 percent revenue growth offsets minor EPS miss. - Earnings Risk - Cổng thông tin điện tử Tỉnh Sơn La

FierceBiotech麦克森以12.5亿美元将外科部门少数股权置换给阿波罗基金。

FierceBiotechAcuityMD raises $80M to help bolster AI in the medtech industry

FierceBiotechAACR: NCI leader Letai battles ‘misinformation’ to assure anxious researchers that ‘funding is strong’

FierceBiotechMerck goes with Google for AI push, striking enterprise partnership worth up to $1B

BioWorldAppointments and advancements for April 22, 2026

BioWorldFinancings for April 22, 2026

BioWorldIn the clinic for April 22, 2026

BioWorldOther news to note for April 22, 2026